Clinical Trial

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

Study acronym: TARMAC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-02-26; most recent amendment 2026-02-13.
Status change: Not Yet Recruiting → Recruiting 2026-02-13
Trial Details
NCT Number NCT06291064
Lead Sponsor University of Chicago
Conditions Triple Negative Breast Cancer
Enrollment 85 participants
Start Date 2025-03-18
Primary Completion 2029-06 (estimated)
Study Completion 2032-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-17